دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Editorial introductions
Editor(s): McCune, W. Joseph; England, Bryant R.
doi : 10.1097/BOR.0000000000000793
Current Opinion in Rheumatology: May 2021 - Volume 33 - Issue 3 - p v
Editorial: Quinacrine: au Revoir or Adieu? This safe and effective drug should be reintroduced
McCune, W. Joseph
doi : 10.1097/BOR.0000000000000797
Current Opinion in Rheumatology: May 2021 - Volume 33 - Issue 3 - p 219-220
The use of mycophenolate mofetil area under the curve
Chakrabarti, Katherinea; Frame, Davidb; Al Abbas, Mousac; McCune, W. Josepha
doi : 10.1097/BOR.0000000000000799
Current Opinion in Rheumatology: May 2021 - Volume 33 - Issue 3 - p 221-232
Although mycophenolate mofetil (MMF) has been used successfully to treat a myriad of autoimmune diseases, its complex pharmacokinetics make it difficult to determine the true drug exposure for an individual patient. This review summarizes the body of literature focused on the gold standard measurement of the area under the curve (AUC) of mycophenolic acid (MPA), the active metabolite of MMF.
Recent advances in the treatment of neuromyelitis optica spectrum disorders
Romeo, Andrew R.
doi : 10.1097/BOR.0000000000000791
Current Opinion in Rheumatology: May 2021 - Volume 33 - Issue 3 - p 233-239
This review examines recently published randomized placebo-controlled trials for the treatment of neuromyelitis optica spectrum disorders (NMOSD).
Treatment for systemic sclerosis-associated interstitial lung disease
Roofeh, Davida; Lescoat, Alaina,b,c; Khanna, Dinesha
doi : 10.1097/BOR.0000000000000795
Current Opinion in Rheumatology: May 2021 - Volume 33 - Issue 3 - p 240-248
This review provides an overview of the current treatments for systemic sclerosis-interstitial lung disease (SSc-ILD) and proposes a conceptual framework for disease management with case scenarios.
Practical management strategies for benign hypermobility syndromes
Minhas, Deeba
doi : 10.1097/BOR.0000000000000798
Current Opinion in Rheumatology: May 2021 - Volume 33 - Issue 3 - p 249-254
Patients with symptomatic hypermobility syndrome such as hypermobile Ehlers-Danlos syndromes (hEDS) and hypermobility spectrum disorders (HSD) commonly present to rheumatologists with joint pain and functional disability. Providers often have difficulty with diagnosis due to a lack of knowledge on the range of associated manifestations and the available therapeutic modalities. This review will discuss recent updates on diagnostic measures and treatment options for rheumatologists to help patients navigate hEDS/HSD.
COVID-19 and rheumatoid arthritis
D'Silva, Kristin M.a,b,c; Wallace, Zachary S.a,b,c
doi : 10.1097/BOR.0000000000000786
Current Opinion in Rheumatology: May 2021 - Volume 33 - Issue 3 - p 255-261
The coronavirus disease 2019 (COVID-19) pandemic has caused significant morbidity and mortality worldwide. Patients with rheumatoid arthritis (RA) face unique challenges during the pandemic, including concerns regarding infection risk, drug shortages, limited access to care, social isolation, and mental health. This review will examine the multifaceted impacts of the COVID-19 pandemic on patients living with RA.
Telerheumatology: before, during, and after a global pandemic
Matsumoto, Rachel A.a; Barton, Jennifer L.a,b
doi : 10.1097/BOR.0000000000000790
Current Opinion in Rheumatology: May 2021 - Volume 33 - Issue 3 - p 262-269
In early 2020, the COVID-19 global pandemic shifted most healthcare to remote delivery methods to protect patients, clinicians, and hospital staff. Such remote care delivery methods include the use of telehealth technologies including clinical video telehealth or telephone visits. Prior to this, research on the acceptability, feasibility, and efficacy of telehealth applied to rheumatology, or telerheumatology, has been limited.
Osteoporosis and fractures in rheumatoid arthritis
Wysham, Katherine D.a; Baker, Joshua F.b; Shoback, Dolores M.c
doi : 10.1097/BOR.0000000000000789
Current Opinion in Rheumatology: May 2021 - Volume 33 - Issue 3 - p 270-276
Rheumatoid arthritis (RA) is associated with increased risk for osteoporotic fracture. We highlight RA-specific risk factors for bone mineral density (BMD) loss and fractures and considerations regarding the diagnosis and treatment of osteoporosis in patients with RA.
Glucocorticoid and opioid use in rheumatoid arthritis management
Moore, Meriah N.a; Wallace, Beth I.a,b
doi : 10.1097/BOR.0000000000000788
Current Opinion in Rheumatology: May 2021 - Volume 33 - Issue 3 - p 277-283
Glucocorticoids and opioids are longstanding, common treatments for rheumatoid arthritis (RA) symptoms. High-quality clinical trials have established that glucocorticoids improve outcomes in RA, but debate continues as to whether their benefits outweigh their risks. We reviewed recent studies on patterns of glucocorticoid and opioid prescribing in RA, and associated harms.
Interstitial lung disease throughout the rheumatoid arthritis disease course
McDermott, Gregory C.a,c; Doyle, Tracy J.b,c; Sparks, Jeffrey A.a,c
doi : 10.1097/BOR.0000000000000787
Current Opinion in Rheumatology: May 2021 - Volume 33 - Issue 3 - p 284-291
To summarize the current understanding of rheumatoid arthritis-associated interstitial lung disease (RA-ILD) throughout the rheumatoid arthritis (RA) disease course from preclinical to established disease.
Impact of rheumatoid arthritis and biologic and targeted synthetic disease modifying antirheumatic agents on cancer risk and recurrence
Singh, Namrataa; Li, Christopher I.b
doi : 10.1097/BOR.0000000000000796
Current Opinion in Rheumatology: May 2021 - Volume 33 - Issue 3 - p 292-299
Several new therapeutic drugs are now available for the management of rheumatoid arthritis (RA). Given that RA has been associated with an increased risk of certain cancers like lymphoma and lung cancer, concern remains about the safety of (newer) immunosuppressants used in RA management as it relates to the risk of cancer.
Role of Janus Kinase inhibitors in rheumatoid arthritis treatment
Reddy, Virginiaa,b; Cohen, Stanleya,c,d
doi : 10.1097/BOR.0000000000000792
Current Opinion in Rheumatology: May 2021 - Volume 33 - Issue 3 - p 300-306
To review recently published articles on use of Janus Kinase inhibitors (Jaki) in the clinic for rheumatoid arthritis (RA).
